甘李药业
(603087)
| 流通市值：259.32亿 | | | 总市值：290.13亿 |
| 流通股本：5.31亿 | | | 总股本：5.94亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 560,334,209.7 | 2,608,036,951.05 | 1,905,670,877.67 | 1,229,765,113.65 |
| 营业收入 | 560,334,209.7 | 2,608,036,951.05 | 1,905,670,877.67 | 1,229,765,113.65 |
| 二、营业总成本 | 541,954,966.18 | 2,306,681,448.38 | 1,645,843,381.45 | 1,108,907,254.24 |
| 营业成本 | 152,249,465.95 | 697,421,415.19 | 481,189,719.14 | 322,655,986.2 |
| 税金及附加 | 6,264,933.61 | 24,262,877.27 | 17,933,843.14 | 12,493,109.55 |
| 销售费用 | 227,086,625 | 945,947,681.96 | 703,633,555.05 | 465,243,177.81 |
| 管理费用 | 43,299,233.12 | 216,749,734.43 | 141,626,147.56 | 100,695,377.33 |
| 研发费用 | 133,120,155.74 | 501,022,439.64 | 369,945,734.16 | 261,962,985.39 |
| 财务费用 | -20,065,447.24 | -78,722,700.11 | -68,485,617.6 | -54,143,382.04 |
| 加:公允价值变动收益 | 85,501,251.91 | -17,916,475.02 | -17,576,525.82 | 9,902,075.97 |
| 加:投资收益 | 2,265,318.1 | 63,331,043.01 | 59,839,944.9 | 21,034,510.73 |
| 资产处置收益 | 580,914.39 | 339,265.71 | 45,822.47 | 45,822.47 |
| 资产减值损失(新) | 49,622.31 | -39,827,886.2 | -3,352,763.4 | -4,326,667.96 |
| 信用减值损失(新) | - | -15,964,110.46 | 4,492,847.21 | 5,476,246.03 |
| 其他收益 | 6,339,484.78 | 23,968,646.18 | 13,936,831.47 | 11,053,501.82 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 113,115,835.01 | 315,285,985.89 | 317,213,653.05 | 164,043,348.47 |
| 加:营业外收入 | 519,781.04 | 4,122,559.53 | 2,931,333.37 | 2,185,720.84 |
| 减:营业外支出 | 75,272.07 | 13,267,468.18 | 9,123,853.22 | 6,535,466.78 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 113,560,343.98 | 306,141,077.24 | 311,021,133.2 | 159,693,602.53 |
| 减:所得税费用 | 17,556,110.25 | -34,090,412.95 | 44,545,285.75 | 25,538,397.62 |
| 六、净利润 | 96,004,233.73 | 340,231,490.19 | 266,475,847.45 | 134,155,204.91 |
| 持续经营净利润 | 96,004,233.73 | 340,231,490.19 | 266,475,847.45 | 134,155,204.91 |
| 归属于母公司股东的净利润 | 96,004,278.2 | 340,068,569.84 | 266,475,880.66 | 134,155,242.69 |
| 少数股东损益 | -44.47 | 162,920.35 | -33.21 | -37.78 |
| (一)基本每股收益 | 0.16 | 0.6 | 0.47 | 0.24 |
| (二)稀释每股收益 | 0.16 | 0.6 | 0.47 | 0.24 |
| 八、其他综合收益 | -110,985.06 | 375,299.98 | 869,456.92 | 1,789,558.67 |
| 归属于母公司股东的其他综合收益 | -110,985.06 | 375,299.98 | 869,456.92 | 1,789,558.67 |
| 九、综合收益总额 | 95,893,248.67 | 340,606,790.17 | 267,345,304.37 | 135,944,763.58 |
| 归属于母公司股东的综合收益总额 | 95,893,293.14 | 340,443,869.82 | 267,345,337.58 | 135,944,801.36 |
| 归属于少数股东的综合收益总额 | -44.47 | 162,920.35 | -33.21 | -37.78 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-31 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |